Preamble 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and the Council ( 1 ) , and in particular Article 14 in conjunction with Article 17 thereof,
Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Article 17 of Regulation (EC) No 470/2009 requires that the maximum residue limit (MRL) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry is established in a Regulation.
recital 2recital 2
(2) Table 1 of the Annex to Commission Regulation (EU) No 37/2010 ( 2 ) sets out the pharmacologically active substances and their classification regarding MRLs in foodstuffs of animal origin.
recital 3recital 3
(3) Gamithromycin is already included in that table as an allowed substance for bovine species, applicable to fat, liver and kidney, excluding animals producing milk for human consumption and for porcine species, applicable to muscle, skin and fat, liver and kidney.
recital 4recital 4
(4) An application for the extension of the existing entry for gamithromycin to ovine species has been submitted to the European Medicines Agency (EMA).
recital 5recital 5
(5) According to Article 5 of Regulation (EC) No 470/2009, the EMA is to consider using MRLs established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or MRLs established for a pharmacologically active substance in one or more species for other species.
recital 6recital 6
(6) The EMA has considered that the extrapolation of the extended entry for gamithromycin to all ruminants except bovine is appropriate.
recital 7recital 7
(7) Regulation (EU) No 37/2010 should therefore be amended accordingly.
recital 8recital 8
(8) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
Article 1
The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
Annex 1ANNEX
In Table 1 of the Annex to Regulation (EU) No 37/2010, the entry for the substance ‘gamithromycin’ is replaced by the following:
Pharmacologically active Substance Marker residue Animal Species MRLs Target Tissues Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009) Therapeutic Classification ‘Gamithromycin Gamithromycin All ruminants except bovine 50 μg/kg Muscle Not for use in animals producing milk for human consumption Anti-infectious agents/Antibiotics’ 50 μg/kg Fat 300 μg/kg Liver 200 μg/kg Kidney Bovine 20 μg/kg Fat 200 μg/kg Liver 100 μg/kg Kidney Porcine 100 μg/kg Muscle NO ENTRY 100 μg/kg Skin and fat in natural proportions 100 μg/kg Liver 300 μg/kg Kidney